All Oncology News

Lasofoxifene was well tolerated and had early activity signals in patients with HR-positive, HER2-negative, locally advanced breast cancer.

The program supports early-career researchers and helps build a cancer research workforce that better represents the diversity of America.

The oncology community must reconsider its approach to defining optimal dosing and scheduling of antineoplastic agents.

Neoadjuvant SHR-A1811 plus pyrotinib generated response and had a manageable safety profile in HER2+ breast cancer.

SHR-A1921 showcased early efficacy with a manageable safety profile in patients with platinum-resistant ovarian cancer.

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.

Secondary metastatic involvement in the musculoskeletal system due to primary cancers and MBD affect patient quality of life and create gaps in care.

Michel Delforge, MD, PhD, discusses an indirect comparison of cilta-cel vs standard-of-care regimens in lenalidomide-refractory multiple myeloma.

Casdatifan was well tolerated and had durable clinical activity in patients with metastatic clear cell renal cell carcinoma.

David Pellman, MD, and Matthew Vander Heiden, MD, PhD of Dana-Farber Cancer Institute have been named to the National Academy of Medicine.

A rolling NDA seeking the approval of avutometinib plus defactinib in recurrent KRAS-mutant low-grade serous ovarian cancer has been submitted to the FDA.

The phase 2 study of masofaniten plus enzalutamide in mCRPC naive to second-generation antiandrogen therapy has been discontinued.

Ameluz-PDT generated statistically significant target lesion clearance outcomes vs placebo-PDT in superficial basal cell carcinoma.

In case you missed any, read a recap of every episode of OncLive On Air that aired in October 2024.

This roundup includes exclusive insights from 23 clinicians and key data on the top abstracts coming out of the 2024 ESMO Annual Meeting.

Marc J. Braunstein, MD, PhD, discusses the diagnosis, prevention, and treatment of patients with veno-occlusive disease post-transplant.

Hope Rugo, MD, FASCO, discusses the FDA approval of inavolisib, how it will be incorporated into care, and the patient population evaluated in INAVO120.

Sheldon M. Feldman, MD, discusses disparities, post-treatment care, and technological advancements in breast cancer during Breast Cancer Awareness Month.

Domenica Lorusso, MD, PhD, and Premal Thaker, MD, highlight the upcoming phase 3 ROSELLA trial of relacorilant in platinum-resistant ovarian cancer.

Docetaxel treatment was associated with significantly less taxane-induced peripheral neuropathy vs paclitaxel in Black patients with breast cancer.

An NDA seeking the approval of sacituzumab tirumotecan for EGFR-mutant non–small cell lung cancer is under review by the NMPA’s CDE.

First-line sugemalimab plus chemotherapy has received UK approval for metastatic NSCLC without EGFR-sensitizing mutations or ALK/ROS1/RET alterations.

Results of the TALAPRO-2 trial showed that a novel prostate cancer therapy has a higher overall survival rate compared to the standard of care drug alone.

John Strickler, MD, details the latest data on the novel c-Met–targeted ADC telisotuzumab adizutecan and how the agent could affect the treatment of CRC.

The FDA has granted regenerative medicine advanced therapy to ALLO-316 in CD70-positive advanced or metastatic renal cell carcinoma.

The FDA has extended the PDUFA date for sotorasib plus panitumumab application in KRAS G12C+ metastatic colorectal cancer.

Laura J. Chambers, DO, discusses the roles of niraparib and olaparib in ovarian cancer and the importance of patient communication throughout treatment.

Bradley C. Carthon, MD, PhD, discusses recent data and the evolving treatment landscape in prostate cancer.

A Roswell Park study reveals the evolutionary stability of the naked mole-rat’s genome, and implications for drug development.

The FDA has announced that BioZorb Markers and BioZorb LP Markers should no longer be used.